The case stems from Keenan’s victory in the second Rolex Grand Prix qualifier aboard Kick On, her 12-year-old Dutch Warmblood stallion. Following their winning round in Aachen, Kick On was selected for routine anti-doping and medication control. Lab results subsequently revealed the presence of triamcinolone acetonide, a corticosteroid widely used in equine veterinary medicine to manage joint inflammation.

The Fast-Track Resolution

Because triamcinolone acetonide is classified by the FEI as a "Controlled Medication" - a substance therapeutic in nature, as opposed to a banned performance enhancer - and because Keenan maintains a clean record with no prior anti-doping violations, she was eligible to utilize the FEI’s streamlined administrative procedure.

By opting for the Fast Track agreement, Keenan avoids a formal tribunal hearing and a suspension, but faces strict administrative consequences:

  • Financial Penalties: A fine of 1,500 Swiss Francs ($1,750 USD), plus 1,000 Swiss Francs in administrative costs.

  • Forfeiture of Results: Disqualification from the class, resulting in the loss of her placings, prize money, and World Ranking points earned during the class.

Keenan Responds: "An Anomaly"

Throughout the inquiry, Keenan maintained complete transparency with governing officials. In a statement addressing the finding, she emphasized that Kick On’s treatment had been administered well outside the FEI’s published 7-day detection time guideline.

"I worked openly with the FEI and my veterinarians throughout the entire process to determine that the detection of triamcinolone acetonide during competition was unforeseen," Keenan said. "My veterinarians and I adhered to the guidelines established by the FEI, and that the drug was still detectable in the joint is an anomaly. Nothing is more important to me than the care and welfare of my horses. My team works diligently to comply with competition regulations, and that is what we did in this case."